Business
Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress
--Unblinded safety data from Phase 2b QUALITY study expected in the second quarter of calendar 2025 -- --Topline efficacy and safety data for Phase 2b extension maintenance study expected in the second quarter of calendar 2025 -- --With positive Phase 2b QUALITY study, Veru plans for end of Phase 2 meeting with FDA to discuss Phase 3 clinical program -- --Company to host conference call and webcast today at 8:00 a.m. ET-- MIAMI, FL, May 08, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a la
About this update from Veru Inc.
[{"type":"image","alt":"Veru Inc.","displaySize":"","headline":null,"caption":"Veru Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":214,"url":"https://media.zenfs.com/en/globenewswire.com/0a5f4ba487ea74752851101a11482743"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/mewu0yec4GXSU1yHV5yukA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTMwMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/0a5f4ba487ea74752851101a11482743","width":300,"height":214}},"lazy":false},{"type":"text","content":"--Unblinded safety data from Phase 2b QUALITY study expected in the second quarter of calendar 2025 --","length":102,"tagName":"p"},{"type":"text","content":"--Topline efficacy and safety data for Phase 2b extension maintenance study expected in the second quarter of calendar 2025 --","length":126,"tagName":"p"},{"type":"text","content":"--With positive Phase 2b QUALITY study, Veru plans for end of Phase 2 meeting with FDA to discuss Phase 3 clinical program --","length":125,"tagName":"p"},{"type":"text","content":"--Company to host conference call and webcast today at 8:00 a.m. ET--","length":69,"tagName":"p"},{"type":"text","content":"MIAMI, FL, May 08, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced financial results for its fiscal 2025 second quarter and provided an update on progress of its clinical development programs.","length":366,"tagName":"p"},{"type":"text","content":"“In addition to our previously disclosed robust and exciting topline efficacy data from the enobosarm Phase 2b QUALITY study, we are now looking forward to the near-term Company catalysts this calendar quarter including the unblinded safety data from the enobosarm Phase 2b QUALITY study as well as the topline efficacy and safety data from the Phase 2b extension maintenance study. The Phase 2b extension study should show us what happens to patients when they stop GLP-1 receptor agonist treatment but remain on enobosarm. The treatment objective is for patients to have a healthier option for choosing to stop GLP-1s without the fear of fat regain,” said Mitchell Steiner, M.D., Chairman, President, and Chief Executive Officer of Veru. “We also expect to submit our End of Phase 2 meeting ...